HUP9802945A2 - 1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállítására - Google Patents

1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállítására

Info

Publication number
HUP9802945A2
HUP9802945A2 HU9802945A HUP9802945A HUP9802945A2 HU P9802945 A2 HUP9802945 A2 HU P9802945A2 HU 9802945 A HU9802945 A HU 9802945A HU P9802945 A HUP9802945 A HU P9802945A HU P9802945 A2 HUP9802945 A2 HU P9802945A2
Authority
HU
Hungary
Prior art keywords
naphth
tetrahydropyridine
lateral sclerosis
amyotrophic lateral
ylethyl
Prior art date
Application number
HU9802945A
Other languages
English (en)
Inventor
Patrice Douillet
Jacqueline Fournier
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9512635A external-priority patent/FR2740343B1/fr
Application filed by Sanofi filed Critical Sanofi
Publication of HUP9802945A2 publication Critical patent/HUP9802945A2/hu
Publication of HUP9802945A3 publication Critical patent/HUP9802945A3/hu
Publication of HU222039B1 publication Critical patent/HU222039B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A találmány a 1-[2-(naft-2-il)-etil]-4-[3-(triflűőr-metil)-fenil]-1,2,3,6-tetrahidrő-piridin vagy annak gyógyászatilag elfőgadhatósavakkal alkőtőtt addíciós sói alkalmazására vőnatkőzik izőmsőrvadásőslaterális szklerózis (ALS) kezelésére alkalmas gyógyszerelőállítására, önmagában, vagy 2-aminő-6-(triflűőr-metőxi)-benzőtiazőllal, illetve IGF-1-gyel vagy BDNF-fel kőmbinációban, ahőlaz IGF-1 inzűlinszerű növekedési faktőr 1-et, a BDNF agyból származóneűrőtróf faktőrt jelent. ŕ
HU9802945A 1995-10-26 1996-10-25 1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállítására HU222039B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9512635A FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR9607336 1996-06-13
PCT/FR1996/001674 WO1997015304A1 (fr) 1995-10-26 1996-10-25 Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique

Publications (3)

Publication Number Publication Date
HUP9802945A2 true HUP9802945A2 (hu) 1999-04-28
HUP9802945A3 HUP9802945A3 (en) 1999-05-28
HU222039B1 HU222039B1 (hu) 2003-03-28

Family

ID=26232287

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802945A HU222039B1 (hu) 1995-10-26 1996-10-25 1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállítására

Country Status (28)

Country Link
US (1) US6043251A (hu)
EP (1) EP0866704B1 (hu)
JP (1) JP3468526B2 (hu)
KR (1) KR100472793B1 (hu)
CN (1) CN1104241C (hu)
AT (1) ATE200423T1 (hu)
AU (1) AU719342B2 (hu)
BR (1) BR9611124A (hu)
CA (1) CA2235747C (hu)
CY (1) CY2279B1 (hu)
CZ (1) CZ293360B6 (hu)
DE (1) DE69612510T2 (hu)
DK (1) DK0866704T3 (hu)
EE (1) EE04177B1 (hu)
ES (1) ES2159362T3 (hu)
GR (1) GR3036027T3 (hu)
HK (1) HK1016904A1 (hu)
HU (1) HU222039B1 (hu)
IL (1) IL124091A (hu)
IS (1) IS1961B (hu)
NO (1) NO316256B1 (hu)
NZ (1) NZ320355A (hu)
PT (1) PT866704E (hu)
SI (1) SI0866704T1 (hu)
SK (1) SK284099B6 (hu)
TR (1) TR199800717T2 (hu)
UA (1) UA57004C2 (hu)
WO (1) WO1997015304A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
EP2305252A1 (en) * 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CA2652251A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2672731A1 (fr) * 1991-02-07 1992-08-14 France Telecom Procede d'oxydation localisee enterree d'un substrat de silicium et circuit integre correspondant.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
SI0866704T1 (en) 2001-08-31
CA2235747C (en) 2006-01-03
SK284099B6 (sk) 2004-09-08
TR199800717T2 (xx) 1998-09-21
WO1997015304A1 (fr) 1997-05-01
CA2235747A1 (en) 1997-05-01
GR3036027T3 (en) 2001-09-28
EE9800132A (et) 1998-10-15
SK52698A3 (en) 1998-09-09
DE69612510D1 (de) 2001-05-17
NO981856D0 (no) 1998-04-24
JPH11515012A (ja) 1999-12-21
HU222039B1 (hu) 2003-03-28
NZ320355A (en) 2000-03-27
DK0866704T3 (da) 2001-07-16
UA57004C2 (uk) 2003-06-16
CZ129698A3 (cs) 1998-07-15
HUP9802945A3 (en) 1999-05-28
BR9611124A (pt) 1999-05-11
ES2159362T3 (es) 2001-10-01
EP0866704A1 (fr) 1998-09-30
NO981856L (no) 1998-06-11
AU719342B2 (en) 2000-05-04
KR19990067057A (ko) 1999-08-16
US6043251A (en) 2000-03-28
IS1961B (is) 2004-11-15
CZ293360B6 (cs) 2004-04-14
EP0866704B1 (fr) 2001-04-11
EE04177B1 (et) 2003-12-15
MX9803271A (es) 1998-09-30
IS4722A (is) 1998-04-21
JP3468526B2 (ja) 2003-11-17
IL124091A (en) 2003-10-31
AU7308496A (en) 1997-05-15
CN1202826A (zh) 1998-12-23
HK1016904A1 (en) 1999-11-12
DE69612510T2 (de) 2001-11-22
KR100472793B1 (ko) 2005-06-16
CY2279B1 (en) 2003-07-04
ATE200423T1 (de) 2001-04-15
CN1104241C (zh) 2003-04-02
NO316256B1 (no) 2004-01-05
PT866704E (pt) 2001-07-31

Similar Documents

Publication Publication Date Title
HUP9802945A2 (hu) 1-[2-(Naft-2-il)-etil]-4-[3-(trifluor-metil)-fenil]-1,2,3,6-tetrahidro-piridin alkalmazása izomsorvadásos laterális szklerózis kezelésére használható gyógyászati készítmények előállítására
UA40587C2 (uk) Метансульфонат (е)-3-[2-h-бутил-1{(4-карбоксифеніл)метил}-1н-імідазол-5-іл]-2-(2-тієніл)метил-2-пропенової кислоти, спосіб його одержання, фармацевтична композиція на його основі
ATE238280T1 (de) Verwendung eines pharmazeutisch geeigneten salzes von (3r,2'r)-3-((cyclopentyl- hydroxyphenylacetyl)oxy)-1,1-dimethyl- pyrrolidinium zur herstellung eines arzneimittels
DE69811492D1 (de) Benzonaphthyridine
EP0410114A3 (en) Use of 4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)-1-(4-fluorophenyl)-butanol in pharmaceutical compositions for the treatment of ischemia in brain
DE59607887D1 (de) Verfahren zur herstellung von optisch aktivem 1-(p-methoxybenzyl)-1,2,3,4,5,6,7,8-octahydroisochinolin
DE69231883T2 (de) 4-(1,1-Dialkoxycarbonyl-Alkyl)Azetidin-2-on-Derivate zur Herstellung von 4-(1-Carboxy-Alkyl)Azetidin-2-on-Derivaten
ATE100451T1 (de) Substituierte bisazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE156490T1 (de) Neue hydrazino und hydroxyamino-14-beta- hydroxyandrostan-derivate mit kardiotonischer aktivität, ein verfahren zu ihrer herstellung und pharmaceutische präparate davon
DE69432000D1 (de) Verwendung von Tetrahydropyridinderivaten zur Herstellung von Kardioprotektiven Medikamenten
DE69528902T2 (de) Neue verwendung und neue derivate von imidazol, ihrer herstellung, zwischenprodukte, und verwendung als arzneimittel
DK0950052T3 (da) Fremgangsmåde til fremstilling af et tetrahydropyridin-derivat
DE50000896D1 (de) Verfahren zur Herstellung von Pyrrolen
DE59010873D1 (de) Verwendung von N-(Aminoacyl)-aminosäuren zur Herstellung von dopaminergen und gonadotropen Arzneimitteln.
ATE193445T1 (de) Verwendung des alpha,alpha-diphenylessigsäure-4- (n-methyl-piperidyl)esters als spasmoanalgetikum

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20030127

HPC4 Succession in title of patentee

Owner name: SANOFI-SYNTHELABO, FR

MM4A Lapse of definitive patent protection due to non-payment of fees